��ɫ��

��ɫ��

Events

Resources For

Abstract Details

Title Safety Profile of Bapineuzumab in a Phase 2 Trial of Mild-to-Moderate Alzheimer[apos]s Disease (AD)

Topic Aging and Dementia

Presentation(s) (-)

Poster/Presentation
Number 005

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Lawrence S. Honig, MD, PhD, FAAN (Columbia University Vagelos College of Physicians & Surgeons)	Dr. Honig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Honig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Honig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Honig has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Honig has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cortexyme. Dr. Honig has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Legal Firms . The institution of Dr. Honig has received research support from Roche. The institution of Dr. Honig has received research support from Eisau. Dr. Honig has received research support from Alector. The institution of Dr. Honig has received research support from Transposon.
Sid Gilman, MD, FAAN	Dr. Gilman has nothing to disclose.
	No disclosure on file
Ronald S. Black, MD (Pfizer)	No disclosure on file
Michael Grundman, MD, MPH (GLOBAL R&D PARTNERS, LLC)	Dr. Grundman has received personal compensation for serving as an employee of Global R&D Partners.
Gordon S. Francis, MD, FAAN	No disclosure on file
	No disclosure on file
	No disclosure on file